CIK 0001228627 · Non-accelerated filer<br>Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113516358
- Phone
- (984) 884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,211,769
- in 7 filings, $50K under 10b5-1 plans
Net −$3,211,769. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Foundation Fighting Blindness Retinal Degeneration Fund −$2.8M Director sold 15% of stake
- Gagnon Robert E. −$177K Chief Financial Officer sold 7% of stake
- Magrath George −$145K Chief Executive Officer sold 2% of stake
- YERXA BENJAMIN R −$117K President sold 5% of stake
- SCHACHLE JOSEPH K −$17K Chief Operating Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-22 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | Purchase | +3,500 | $1.77 | $6K | 78,500 |
| 2024-05-17 | Magrath George Chief Executive Officer | Purchase | +5,000 | $1.75 | $9K | 430,000 |
| 2024-04-11 | Pepose Jay Director | Grant or award | +32,000 | 139,315 | ||
| 2024-04-11 | Pepose Jay Director | Grant or award · Stock Option (right to buy) | +48,000 | 48,000 | ||
| 2024-03-21 | SCHACHLE JOSEPH K Chief Operating Officer | Purchase | +2,000 | $2.05 | $4K | 2,000 |
| 2024-03-21 | Jhaveri Nirav S. Chief Financial Officer | Purchase | +10,000 | $2.10 | $21K | 150,000 |
| 2024-03-18 | Magrath George Chief Executive Officer | Purchase | +25,000 | $1.96 | $49K | 425,000 |
| 2024-02-12 | Jhaveri Nirav S. Chief Financial Officer | Grant or award | +140,000 | 140,000 | ||
| 2024-02-12 | Jhaveri Nirav S. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +210,000 | 210,000 | ||
| 2024-02-12 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | Grant or award | +75,000 | 75,000 | ||
| 2024-02-12 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | Grant or award · Employee Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2024-01-18 | Hoffmann Bernhard SVP of Corp. Dev. | Grant or award | +20,000 | 162,697 | ||
| 2024-01-18 | Hoffmann Bernhard SVP of Corp. Dev. | Grant or award · Employee Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2024-01-18 | Zaremba Rabourn Amy SVP of Finance | Grant or award | +40,000 | 82,658 | ||
| 2024-01-18 | Zaremba Rabourn Amy SVP of Finance | Grant or award · Employee Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2024-01-10 | Zaremba Rabourn Amy SVP of Finance | Shares withheld for taxes | −3,950 | $3.27 | $13K | 42,658 |
Page 7 of 7 · 136 trades